Third Bevacizumab Biosimilar, Bevacizumab-Maly, Approved by FDA Across Various Cancer Indications


Bevacizumab-maly was approved by the FDA across numerous cancer indications, becoming the third FDA-approved bevacizumab biosimilar.

The FDA has approved the second bevacizumab (Avastin) biosimilar, bevacizumab-maly (Alymsys), across a variety of cancer indications, according to a press release from Amneal Pharmaceuticals.1,2

The approval of the VEGF inhibitor is the second of 3 approvals that developer Amneal expects in 2022.

“With the U.S. approval of our second biosimilar, [bevacizumab-maly] we are continuing our momentum and establishing our presence in the $28 billion U.S. biosimilars market. By combining partner assets with our own key capabilities, we are on a clear path to becoming a meaningful player in this high growth category. Biosimilars represent the next wave of affordable medicines in the U.S. and are closely aligned with our strategy to provide high quality, affordable medicines to as many patients as possible,” Chirag Patel and Chintu Patel, co-chief executive officers at Amneal Pharmaceuticals, said in a press release.

Bevacizumab-maly can be used across many tumor types, including the following:

Indications for bevacizumab biosimilar bevacizumab-maly.

Indications for bevacizumab biosimilar bevacizumab-maly.

The biosimilar has several warnings and precautions for several toxicities, including severe and fatal hemorrhage; arterial and venous thromboembolic events; hypertension, hypertensive crisis, and hypertensive encephalopathy; renal injury, proteinuria, and nephrotic syndrome; posterior reversible encephalopathy syndrome; embryo-fetal toxicity; ovarian failure; congestive heart failure; gastrointestinal perforations and fistula; and surgery/wound healing complications and infusion-related reactions. Additionally, treatment-related adverse effects for bevacizumab-maly include epistaxis, hemorrhage, hypertension, exfoliative dermatitis, proteinuria, back pain, headache, rhinitis, taste alteration, dry skin, and lacrimation disorder.

“Through our strategic partnership with a market leader like Amneal, we are excited to see this important product enter the U.S. biosimilar market. For us, this is a great example of our globalization strategy materializing and how innovation and cutting-edge R&D technology can be applied to create high quality, affordable medicines that improve access to critical treatments,” Emmanuelle Lepine, chief executive officer at mAbxience, concluded.


  1. Amneal achieves second U.S. biosimilars approval with ALYMSYS® (bevacizumab-maly). News release. April 13, 2022. Accessed April 19, 2022.
  2. FDA approves Alymsys® (bevacizumab-maly), a biosimilar of bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience. News release. April 18, 2022. Accessed April 19, 2022.
Related Videos
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
Related Content